F.D.A. Refuses to Review Moderna Flu Vaccine

The U.S. Food and Drug Administration (FDA) formally declined to review Moderna’s application for its new mRNA-based influenza vaccine on Tuesday, following a period of heightened scrutiny over the technology by the Department of Health and Human Services under Secretary Robert F. Kennedy Jr. The federal regulator’s refusal to accept the filing marks a significant setback for the biotechnology company as it attempts to expand its messenger RNA portfolio beyond COVID-19. The decision comes at a time of shifting federal policy regarding vaccine oversight and public skepticism voiced by top health leadership regarding the long-term efficacy and safety of the mRNA platform. Moderna had hoped to utilize the accelerated approval pathway for its flu candidate, mRNA-1010, which was designed to target multiple strains of the virus more efficiently than traditional egg-based vaccines. However, the FDA's rejection of the submission suggests that the agency may now require more comprehensive clinical data or a different regulatory approach before moving forward. This development is particularly notable given that the Biden administration had previously championed the technology for its rapid response capabilities during the pandemic. The regulatory hurdle coincides with a broader debate within the U.S. government regarding the future of public health mandates and pharmaceutical innovation. Health Secretary Robert F. Kennedy Jr., a long-standing critic of the traditional vaccine industry, has frequently questioned the rigor of the FDA’s approval processes for mRNA products. Analysts suggest that this rejection could signal a more cautious era for biotech companies seeking federal authorization for new treatments, as the current administration emphasizes a reorganization of health agency priorities. Following the announcement, Moderna’s stock experienced volatility as investors assessed the potential delays in the company's product pipeline. The company stated it remains committed to the technology and will continue to work with regulators to address any concerns. Despite this setback, the firm maintains that its flu vaccine showed promising results in late-stage trials, demonstrating the ability to generate a robust immune response against several common influenza variants.